Developer docs
API playgroundTry for free, no card

Search company profiles

Pleno

Full company profile

uuid0000iz6

Namestring
Pleno
Legal namestring
Pleno Inc.
Websiteurl
plenoinc.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Pleno Inc. is a San Diego-based, venture-backed biotechnology company founded in 2021 that has developed a proprietary biomarker detection technology called Hypercoding, which applies code-multiplexing techniques derived from digital telecommunications to multi-omic sample analysis. The company's commercial product is the RAPTOR benchtop instrument platform, which uses standard 96- or 384-well plate consumables (Plenoid probes) to simultaneously detect up to 10,000 biomarkers per sample across DNA, RNA, methylation, and protein modalities in a single run, with end-to-end workflows under eight hours and claimed 100x sample throughput versus next-generation sequencing (NGS) and 1,000x target multiplexing versus PCR.

The company targets a horizontal set of clinical and research applications — primarily oncology, pharmacogenomics, and proteomics, with secondary use cases in infectious disease, non-invasive prenatal testing (NIPT)/newborn screening, genotyping, and agrigenomics. Its go-to-market is enterprise field sales through an Early Access Program and Apps Lab evaluation services, with full commercial availability of production RAPTOR instruments targeted for early 2025 and the first commercial agreement (Slopes Bio for up to five instruments and 100,000+ samples annually) announced in August 2025. Products are sold research-use-only at this stage, not for diagnostic procedures.

Pleno has raised approximately $80 million in total funding across a Pre-Series A ($15M, May 2022), Series A ($40M, October 2022), and Series B ($25M, December 2024) from investors including Deerfield Management, Foresite Capital, Medical Excellence Capital, and Alexandria Venture Investments. The leadership team includes former executives from Illumina, PacBio, Thermo Fisher Scientific, GenMark Diagnostics (Roche), Amgen, BCG, and McKinsey. The company employed 64 full-time staff as of January 2024 with stated plans for rapid headcount expansion. Recurring revenue is intended to come from sale of Plenoid reagent and consumable kits tied to installed RAPTOR instruments.

Short descriptiontext

Pleno Inc. is a San Diego-based biotechnology company that develops the RAPTOR benchtop instrument and proprietary Hypercoding technology to detect up to 10,000 multi-omic biomarkers per sample in a single run. It serves clinical and research labs across oncology, pharmacogenomics, proteomics, and related genomics applications through direct enterprise sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-omic biomarker detection, clinical genomics instruments, high-plex molecular diagnostics, DNA RNA protein detection, benchtop sequencing instruments
Industry2 codes
PRIMARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Molecular Diagnostics Instruments
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1RAPTOR Instrument Sales
TypeHardware Sales
Description

Sale of RAPTOR benchtop instrument platform to medium to high-throughput labs. Production targeted for late 2024 with general availability in early 2025.

plenoinc.com
2Reagent and Consumable Kits
TypeSubscription Recurring
Description

Recurring revenue from sale of Plenoid probes (Reagent and Consumable Kits) used in RAPTOR instrument runs. Includes custom-designed probes for customer-specific biomarker panels.

plenoinc.com
3Apps Lab Services
TypeProfessional Services
Description

Early access program providing fully automated workflow environment for customer sample processing and data generation. Limited availability for onsite customer evaluations.

plenoinc.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details2 tiers
1RAPTOR Early Access Program
ModelOtherBilling cadencePay-as-you-go
Notes

Early access through Apps Lab for sample processing and evaluation. Limited availability for onsite customer evaluations.

plenoinc.com
2Production Instruments and Consumables
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Direct sales engagement required.

plenoinc.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1RAPTOR
Description

Benchtop instrument platform for multi-omic biomarker detection capable of detecting up to 10,000+ targets per sample with sample throughput scalable from 1-384 samples per run.

plenoinc.com
+1 more record
Core offering1 text field

Pleno develops and sells the RAPTOR benchtop instrument platform powered by its proprietary Hypercoding technology, which performs multiplexed detection of up to 10,000+ biomarkers (DNA, RNA, methylation, and proteins) per sample using standard 96- or 384-well plate consumables. The platform is complemented by Plenoid probe reagent and consumable kits for the RAPTOR workflow and an Apps Lab early-access service for sample processing and customer evaluation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 10,000 targets per sample detection capability vs typical PCR panels of 10-50 targets
+6 more records
Product overview1 text field

Pleno offers the RAPTOR instrument platform as its core product, a benchtop system powered by proprietary Hypercoding technology that enables multi-omic biomarker detection (DNA, RNA, methylation, and proteins) at unprecedented scale—detecting up to 10,000 targets per sample with sample throughput scalable from 1 to 384 samples per run. The system is complemented by Reagent and Consumable Kits containing Plenoid probes that are designed specifically for the RAPTOR workflow. Together, these products form a complete solution for high-throughput biological target detection in applications including oncology, pharmacogenomics, proteomics, infectious diseases, and agrigenomics.

Product and service3 records
1RAPTOR Instrument Platform
CategoryInstrument Platform
Description

Benchtop instrument platform delivering ultra-scalable sample throughput (1-384 samples per run) while detecting 10-10,000+ biomarkers per sample including DNA, RNA, methylation, and proteins. Uses standard 96- or 384-well plate consumables, with 3-4 hour instrument run time and end-to-end workflow typically less than 8 hours. Targeted at medium to high-throughput clinical and research labs.

2Reagent and Consumable Kits (Plenoid Probes)
CategoryConsumables
Description

Plenoid probe kits and consumables containing synthesized circularizable DNA oligos with unique Hypercodes assigned to each biomarker target. Used for target capture, conversion, and detection in the RAPTOR workflow. Sold as recurring revenue consumables, including custom-designed probes for customer-specific biomarker panels.

3Apps Lab Services
CategoryProfessional Services
Description

Early access program providing a fully automated workflow environment for customer sample processing and data generation, with limited availability for onsite customer evaluations of the RAPTOR platform.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-06
Description

Comprehensive commercial agreement for biological target detection and personalized health. Slopes Bio to purchase up to five RAPTOR instruments and consumables for 100,000+ samples annually. Companies jointly developing high-sample-volume applications. First two instruments deployed in Utah production lab September 2025.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-08
Description

Integration of RAPTOR with BioLegend's TotalSeq antibodies for multi-omic biomarker detection. First deployment of early access RAPTOR with Hypercoding technology verified outside development lab. Enables customers to incorporate protein markers into DNA, RNA, or methylation detection panels.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant NGS platform provider with the largest installed base of sequencers globally. Competes with Pleno in clinical genomics and multi-omics, though Illumina's core chemistry (sequencing by synthesis) is fundamentally different from Hypercoding. Several Pleno executives and board members came from Illumina, and Slopes Bio represents a target customer profile that Illumina has historically served.

TypeDirect peer
Description

Developer of the AVITI benchtop sequencer using an alternative chemistry (avidity sequencing) that competes on cost and accessibility in clinical and research labs—directly analogous to Pleno's positioning of RAPTOR. Targets medium-throughput labs seeking NGS alternatives with improved economics, overlapping with Pleno's go-to-market focus.

TypeDirect peer
Description

Long-read sequencing instrument provider (Revio, Onso, Vega) targeting clinical and research labs with high-accuracy sequencing. Competes for the same instrument-purchase budget at medium-to-high-throughput labs. Erik Williamson, Pleno's VP of Engineering, previously launched three PacBio instruments, evidencing close technical positioning.

TypeDirect peer
Description

Developer of nanopore-based sequencing platforms (MinION, PromethION, GridION) offering scalable, real-time DNA/RNA sequencing. Competes with Pleno in the benchtop-to-high-throughput genomic instrument market, particularly for applications requiring flexible sample-to-answer workflows.

TypeDirect peer
Description

Developer of the G4 benchtop sequencer positioned as a low-cost, medium-throughput alternative to Illumina. Targets clinical and research labs seeking affordable sequencing instruments—directly comparable to Plenoroadmap for accessible, multi-omic-capable benchtop instruments.

6MGI Tech
TypeDirect peer
Description

Chinese-headquartered sequencing and multi-omics instrument provider (DNBSEQ platforms) offering cost-competitive alternatives to Illumina. Competes globally in clinical and research genomics, and its expansion into multi-omic reagents and automation parallels Pleno's platform approach.

TypeDirect peer
Description

Developer of mass cytometry and microfluidic instrumentation for multi-omic single-cell analysis. Competes with Plenoin the targeted multi-omic detection market with benchtop-format instruments aimed at translational and clinical research labs.

TypeBroad incumbent
Description

Major life sciences tools provider whose ProteinSimple division offers proteomics and Western blot instruments. Plenoprotegrations with BioLegend (now part of Revvity/Bio-Techne) demonstrate ecosystem adjacency, and Bio-Techne's protein-detection portfolio competes with Plenoprotegrated multi-omic capabilities.

TypeEmerging player
Description

Developer of optical genome mapping instruments (Saphyr) for structural variation detection. While focused on a different genomic application (large structural variants vs. high-plex targeted detection), Bionano competes for instrument-purchase budgets at genomics labs and represents a comparable emerging instrument-platform business model.

TypeBroad incumbent
Description

Major life sciences and diagnostics company whose BioLegend division supplies the TotalSeq antibody reagents integrated with PlenoproRAPTOR platform. Revvity's broader diagnostics and life sciences tools portfolio overlaps with Plenoin clinical genomics and multi-omic detection applications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pleno

Molecular Diagnostics Instrumentsplenoinc.com

Pleno Inc. is a San Diego-based biotechnology company that develops the RAPTOR benchtop instrument and proprietary Hypercoding technology to detect up to 10,000 multi-omic biomarkers per sample in a single run. It serves clinical and research labs across oncology, pharmacogenomics, proteomics, and related genomics applications through direct enterprise sales.

What Pleno does

Pleno Inc. is a San Diego-based, venture-backed biotechnology company founded in 2021 that has developed a proprietary biomarker detection technology called Hypercoding, which applies code-multiplexing techniques derived from digital telecommunications to multi-omic sample analysis. The company's commercial product is the RAPTOR benchtop instrument platform, which uses standard 96- or 384-well plate consumables (Plenoid probes) to simultaneously detect up to 10,000 biomarkers per sample across DNA, RNA, methylation, and protein modalities in a single run, with end-to-end workflows under eight hours and claimed 100x sample throughput versus next-generation sequencing (NGS) and 1,000x target multiplexing versus PCR.

The company targets a horizontal set of clinical and research applications — primarily oncology, pharmacogenomics, and proteomics, with secondary use cases in infectious disease, non-invasive prenatal testing (NIPT)/newborn screening, genotyping, and agrigenomics. Its go-to-market is enterprise field sales through an Early Access Program and Apps Lab evaluation services, with full commercial availability of production RAPTOR instruments targeted for early 2025 and the first commercial agreement (Slopes Bio for up to five instruments and 100,000+ samples annually) announced in August 2025. Products are sold research-use-only at this stage, not for diagnostic procedures.

Pleno has raised approximately $80 million in total funding across a Pre-Series A ($15M, May 2022), Series A ($40M, October 2022), and Series B ($25M, December 2024) from investors including Deerfield Management, Foresite Capital, Medical Excellence Capital, and Alexandria Venture Investments. The leadership team includes former executives from Illumina, PacBio, Thermo Fisher Scientific, GenMark Diagnostics (Roche), Amgen, BCG, and McKinsey. The company employed 64 full-time staff as of January 2024 with stated plans for rapid headcount expansion. Recurring revenue is intended to come from sale of Plenoid reagent and consumable kits tied to installed RAPTOR instruments.

Pleno firmographics

Firmographics
Name
Pleno
Legal name
Pleno Inc.
Website
https://plenoinc.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Pleno Inc. is a San Diego-based biotechnology company that develops the RAPTOR benchtop instrument and proprietary Hypercoding technology to detect up to 10,000 multi-omic biomarkers per sample in a single run. It serves clinical and research labs across oncology, pharmacogenomics, proteomics, and related genomics applications through direct enterprise sales.
Ownership category
akta.pro rank

Pleno industry classification

Industry
Product category
Molecular Diagnostics Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Multi-omic biomarker detection
  • Clinical genomics instruments
  • High-plex molecular diagnostics
  • DNA RNA protein detection
  • Benchtop sequencing instruments

Where Pleno is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pleno business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. RAPTOR Instrument Sales: Sale of RAPTOR benchtop instrument platform to medium to high-throughput labs. Production targeted for late 2024 with general availability in early 2025.
  2. Reagent and Consumable Kits: Recurring revenue from sale of Plenoid probes (Reagent and Consumable Kits) used in RAPTOR instrument runs. Includes custom-designed probes for customer-specific biomarker panels.
  3. Apps Lab Services: Early access program providing fully automated workflow environment for customer sample processing and data generation. Limited availability for onsite customer evaluations.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goRAPTOR Early Access Program
OtherMulti-year contractProduction Instruments and Consumables

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Pleno product offering

Product offering

Core offering

Pleno develops and sells the RAPTOR benchtop instrument platform powered by its proprietary Hypercoding technology, which performs multiplexed detection of up to 10,000+ biomarkers (DNA, RNA, methylation, and proteins) per sample using standard 96- or 384-well plate consumables. The platform is complemented by Plenoid probe reagent and consumable kits for the RAPTOR workflow and an Apps Lab early-access service for sample processing and customer evaluation.

Product overview

Pleno offers the RAPTOR instrument platform as its core product, a benchtop system powered by proprietary Hypercoding technology that enables multi-omic biomarker detection (DNA, RNA, methylation, and proteins) at unprecedented scale—detecting up to 10,000 targets per sample with sample throughput scalable from 1 to 384 samples per run. The system is complemented by Reagent and Consumable Kits containing Plenoid probes that are designed specifically for the RAPTOR workflow. Together, these products form a complete solution for high-throughput biological target detection in applications including oncology, pharmacogenomics, proteomics, infectious diseases, and agrigenomics.

Differentiator

Problem solved

Functional benefit

Brands

  • RAPTOR: Benchtop instrument platform for multi-omic biomarker detection capable of detecting up to 10,000+ targets per sample with sample throughput scalable from 1-384 samples per run.
  • Hypercoding

Products and services

  • RAPTOR Instrument Platform Benchtop instrument platform delivering ultra-scalable sample throughput (1-384 samples per run) while detecting 10-10,000+ biomarkers per sample including DNA, RNA, methylation, and proteins. Uses standard 96- or 384-well plate consumables, with 3-4 hour instrument run time and end-to-end workflow typically less than 8 hours. Targeted at medium to high-throughput clinical and research labs.
  • Reagent and Consumable Kits (Plenoid Probes) Plenoid probe kits and consumables containing synthesized circularizable DNA oligos with unique Hypercodes assigned to each biomarker target. Used for target capture, conversion, and detection in the RAPTOR workflow. Sold as recurring revenue consumables, including custom-designed probes for customer-specific biomarker panels.
  • Apps Lab Services Early access program providing a fully automated workflow environment for customer sample processing and data generation, with limited availability for onsite customer evaluations of the RAPTOR platform.

Quantifiable outcome

  • 10,000 targets per sample detection capability vs typical PCR panels of 10-50 targets
  • +6 more outcomes

Companies that use Pleno

Customer profile

Named customers1 record

Segments7 records

Ideal customer profiles2 records

Pleno technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Pleno partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Slopes Bio, Inc.flagshipStrategic or Co-development Partner · 6 August 2025Comprehensive commercial agreement for biological target detection and personalized health. Slopes Bio to purchase up to five RAPTOR instruments and consumables for 100,000+ samples annually. Companies jointly developing high-sample-volume applications. First two instruments deployed in Utah production lab September 2025.
  • BioLegend (Revvity)coreTechnology or Integration · 8 January 2024Integration of RAPTOR with BioLegend's TotalSeq antibodies for multi-omic biomarker detection. First deployment of early access RAPTOR with Hypercoding technology verified outside development lab. Enables customers to incorporate protein markers into DNA, RNA, or methylation detection panels.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Pleno competitors and assessment

Company assessment

Broad incumbents

  • Illumina: Dominant NGS platform provider with the largest installed base of sequencers globally. Competes with Pleno in clinical genomics and multi-omics, though Illumina's core chemistry (sequencing by synthesis) is fundamentally different from Hypercoding. Several Pleno executives and board members came from Illumina, and Slopes Bio represents a target customer profile that Illumina has historically served.
  • Bio-Techne (ProteinSimple): Major life sciences tools provider whose ProteinSimple division offers proteomics and Western blot instruments. Plenoprotegrations with BioLegend (now part of Revvity/Bio-Techne) demonstrate ecosystem adjacency, and Bio-Techne's protein-detection portfolio competes with Plenoprotegrated multi-omic capabilities.
  • Revvity (formerly PerkinElmer): Major life sciences and diagnostics company whose BioLegend division supplies the TotalSeq antibody reagents integrated with PlenoproRAPTOR platform. Revvity's broader diagnostics and life sciences tools portfolio overlaps with Plenoin clinical genomics and multi-omic detection applications.

Direct peers

  • Element Biosciences: Developer of the AVITI benchtop sequencer using an alternative chemistry (avidity sequencing) that competes on cost and accessibility in clinical and research labs—directly analogous to Pleno's positioning of RAPTOR. Targets medium-throughput labs seeking NGS alternatives with improved economics, overlapping with Pleno's go-to-market focus.
  • Pacific Biosciences (PacBio): Long-read sequencing instrument provider (Revio, Onso, Vega) targeting clinical and research labs with high-accuracy sequencing. Competes for the same instrument-purchase budget at medium-to-high-throughput labs. Erik Williamson, Pleno's VP of Engineering, previously launched three PacBio instruments, evidencing close technical positioning.
  • Oxford Nanopore Technologies: Developer of nanopore-based sequencing platforms (MinION, PromethION, GridION) offering scalable, real-time DNA/RNA sequencing. Competes with Pleno in the benchtop-to-high-throughput genomic instrument market, particularly for applications requiring flexible sample-to-answer workflows.
  • Singular Genomics: Developer of the G4 benchtop sequencer positioned as a low-cost, medium-throughput alternative to Illumina. Targets clinical and research labs seeking affordable sequencing instruments—directly comparable to Plenoroadmap for accessible, multi-omic-capable benchtop instruments.
  • MGI Tech: Chinese-headquartered sequencing and multi-omics instrument provider (DNBSEQ platforms) offering cost-competitive alternatives to Illumina. Competes globally in clinical and research genomics, and its expansion into multi-omic reagents and automation parallels Pleno's platform approach.
  • Standard BioTools (formerly Fluidigm): Developer of mass cytometry and microfluidic instrumentation for multi-omic single-cell analysis. Competes with Plenoin the targeted multi-omic detection market with benchtop-format instruments aimed at translational and clinical research labs.

Emerging players

  • Bionano Genomics: Developer of optical genome mapping instruments (Saphyr) for structural variation detection. While focused on a different genomic application (large structural variants vs. high-plex targeted detection), Bionano competes for instrument-purchase budgets at genomics labs and represents a comparable emerging instrument-platform business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Pleno social profiles

Digital presence

Pleno financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pleno leadership team

Management profile

Number of profiles

Profiles11 records

Pleno funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pleno M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pleno

What does Pleno do?

Pleno develops and sells the RAPTOR benchtop instrument platform powered by its proprietary Hypercoding technology, which performs multiplexed detection of up to 10,000+ biomarkers (DNA, RNA, methylation, and proteins) per sample using standard 96- or 384-well plate consumables. The platform is complemented by Plenoid probe reagent and consumable kits for the RAPTOR workflow and an Apps Lab early-access service for sample processing and customer evaluation.

Is Pleno a public or private company?

Pleno is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pleno founded?

Pleno was founded in 2021. It employs 11 to 50 people.

Where is Pleno based?

Pleno is headquartered in San Diego, United States, in the North America region.

How does Pleno make money?

Three revenue lines are on record. RAPTOR Instrument Sales are the primary driver. The others are reagent and Consumable Kits and apps Lab Services.

Who are Pleno's main competitors?

Broad incumbents on record are Illumina, Bio-Techne (ProteinSimple) and Revvity (formerly PerkinElmer). Direct peers are Element Biosciences, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, Singular Genomics, MGI Tech and Standard BioTools (formerly Fluidigm). Bionano Genomics is listed as an emerging player.

Does Pleno have an API?

No public API is recorded for Pleno.

What industry is Pleno in?

Pleno's product category is Molecular Diagnostics Instruments. Its primary akta.pro industry code is HLAAACAK, Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineMulti-omics Startup Pleno Inc. Announces $15 Million in Pre-Series A FundingPleno Inc. announced the closing of $15 million in Pre-Series A funding, led by Medical Excellence Capital and Alexandria Venture Investments. The capital will support the development of Pleno's Hypercoding instrument platform, which aims to detect up to 10,000 targets per sample with significantly higher throughput than existing PCR or NGS technologies. Biotech veteran Gregory T. Lucier joined the company as Chairman of the Board.Pulse 2.0Pleno: Clinical And Multi-Omics Diagnostics Company Raises $25 Million (Series B)Pleno, a clinical and multi-omics diagnostics company, raised $25 million in Series B funding and appointed Dr. Vik Vaz as CEO. The company will use the funds to scale commercial operations, with key investors Deerfield Management, Foresite Capital, and Medical Excellence Capital remaining committed.VC News DailyPleno Announces $25M Series B RoundPleno announced $25 million in Series B funding and appointed Dr. Vik Vaz as CEO. The San Diego diagnostics company will use the funds to scale commercial operations. Key investors Deerfield Management, Foresite Capital, and Medical Excellence Capital remain committed.GlobeNewswirePleno Deploys its RAPTOR Instrument Platform Available withPleno Inc. deployed its first RAPTOR instrument with BioLegend's TotalSeq antibodies, marking the first external verification of its Hypercoding multi-omic technology. The platform detects over 10,000 biomarkers per sample, with production-ready instruments expected in Q4 2024 and full commercial availability in Q1 2025.Business Wire BlogMulti-omics Startup Pleno Inc. Continues to Strengthen its Board of DirectorsPleno Inc. appointed Mark Gardner, senior vice president of molecular genomics and oncology at Quest Diagnostics, to its board of directors. Gardner brings over 30 years of senior management experience, including roles at Thermo Fisher and Corza Health. Pleno's RAPTORTM instrument platform is set for early customer access in 2023 and commercial availability in 2024.PharmiWeb.comMulti-omics Startup Pleno Inc. Continues to Strengthen its Board of DirectorsPleno Inc. announced that Mark Gardner, Senior Vice President at Quest Diagnostics and former Thermo Fisher executive, has joined its Board of Directors. This appointment follows the company's recent $40 million Series A funding round led by Deerfield Management. The news coincides with updates on Pleno's Hypercoding technology, with its RAPTORTM instrument platform scheduled for early customer access in 2023.BioSpaceMulti-omics Startup Pleno Inc. Expands Leadership Team to Accelerate Development of its Novel Hypercoding TechnologyPleno Inc. appointed Jason Trachewsky as Vice President of Software and Professor Nambi Seshadri to its Scientific Advisory Board to support the development of its Hypercoding technology. The company plans to more than double its San Diego-based team over the next six to nine months as it advances its RAPTOR instrument platform for biological target detection.ZapierMulti-omics Startup Pleno Inc. Announces $40 Million in Series A Funding Led by Deerfield Management with Participation by Foresite CapitalPleno Inc. announced the closing of a $40 million Series A funding round led by Deerfield Management Company with participation from Foresite Capital. The funds will accelerate the development of Pleno’s Hypercoding™ instrument platform, RAPTOR™, which is scheduled for early customer access in 2023 and full availability in 2024. This investment supports the company's goal to disrupt existing sequencing approaches by providing ultra-high plexity targeted biological information for clinical diagnostics and biomedical research.VC News DailyPleno Announces $40 Million in Series APleno Inc., a multi-omic instrument platform company based in San Diego, has closed a $40 million Series A financing round. The round was led by Deerfield Management Company with participation from Foresite Capital. The company's proprietary Hypercoding technology applies signal processing techniques from telecommunications to deliver targeted biological information for clinical testing and biomedical research.FinSMEsPleno Raises $40M in Series A FundingPleno, a company based in San Diego, raised $40 million in Series A funding led by Deerfield Management Company and Foresite Capital. The funds will be used to develop its Hypercoding™ instrument platform, RAPTOR™, scheduled for early customer access in 2023 and full release in 2024.